Kezar, Lupus Nephritis
Kezar Reports Four Patient Deaths in Mid-Stage Lupus Nephritis Study, Pauses Enrollment
William Blair analyst Matt Phipps in a note to investors wrote that despite the patient deaths, the totality of the data still leans in favor of Kezar Life Sciences’ investigational immunoproteasome inhibitor zetomipzomib.
Kezar Life Sciences suspends subject enrolment in trial of lupus nephritis drug
According to the safety findings, four Grade Five serious adverse events were reported during the Phase II PALIZADE trial.
Kezar halts dosing and enrollment in key lupus study after 4 patient deaths
Kezar Life Sciences went all in on its autoimmune candidate zetomipzomib after a restructuring last year. | The voluntary hold comes after Kezar restructured last year to in a bid to support its lupus and hepatitis candidate zetomipzomib.
Kezar Life Sciences Halts Trial of Lupus-Nephritis Treatment After Deaths
Kezar Life Sciences said it voluntarily suspended enrollment and dosing in a clinical trial of a treatment for an autoimmune kidney disease after four patients died.
Setback for Kezar Life Sciences’ Lupus candidate zetomipzomib
Kezar Life Sciences saw its share tumble more than 42% to 40.77 yesterday, after it revealed it was voluntarily pausing enrollment of new patients and dosing of ongoing patients in the Phase IIb PALIZADE clinical trial,
Kezar Life Sciences pauses trial for lupus treatment after patient deaths
Kezar Life Sciences said on Monday it has paused a trial of its experimental drug for lupus to review safety data after four patients died in the mid-stage study. The San Francisco-based company said it had informed the U.
Renal & Urology News4h
Significant Benefit Seen With Obinutuzumab in Lupus Nephritis Trial
Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis.
Artist who tackles lupus in her paintings seeks a kidney donor
Three different versions of Alexandria Wingate appear in a trio of purple paintings the Baltimorean started while a fine art ...
pulmonologyadvisor8h
Nomogram Predicts Lupus Nephritis With Interstitial Fibrosis
Lupus nephritis progression may be faster in patients with interstitial fibrosis/tubular atrophy (IFTA). Now a nomogram may predict it.
BioSpace4d
Roche Looks to Push Gazyva Into Lupus Nephritis With Promising Late-Stage Data
In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis ...
The Pharma Letter1d
Positive Phase III results for Roche’s Gazyva/Gazyvaro in lupus
Swiss pharma giant Roche has announced positive top-line results from the Phase III REGENCY study of Gazyva/Gazyvaro ...
EuropaWire5d
Roche’s Gazyva Shows Breakthrough Results in Treating Lupus Nephritis, Offering Hope for Kidney Disease Patients
Roche has announced positive results from its phase III REGENCY study, showing that its drug Gazyva®/Gazyvaro® (obinutuzumab) ...